RIME enables drug discovery by screening large libraries of AI‑designed probes against thousands of druggable intracellular pockets in primary human cells, directly linking target biology to actionable chemistry programs.
Funding
Funding not disclosed
Founders
Product
Problem
Drug discovery often struggles to identify and validate intracellular protein pockets that are biologically relevant, especially in primary human cells. Without detailed binding and structure‑activity data, many potentially druggable targets remain uncharted, slowing the development of new therapeutics.
Solution
RIME addresses this gap by using large libraries of AI‑designed chemical probes to screen thousands of druggable intracellular pockets directly in primary human cells. The platform links target biology to actionable chemistry by generating target‑specific binding affinities and detailed structure‑activity relationships (SAR) for each pocket. This data enables researchers to prioritize targets that demonstrably influence disease pathways and to design optimized lead compounds for previously inaccessible sites. By integrating computational probe design with cell‑based screening, RIME accelerates the translation of novel biological insights into viable drug discovery programs.
Target Audience
RIME’s services are aimed at pharmaceutical companies and biotech research teams seeking to discover and develop small‑molecule therapeutics against intracellular targets, as well as academic labs focused on target validation and chemical biology.
Features
- AI‑driven design of diverse probe libraries tailored to explore a broad spectrum of intracellular pockets
- High‑throughput screening in primary human cells to capture physiologically relevant target engagement
- Generation of quantitative binding data and SAR profiles for each screened pocket
- Identification of biologically active targets that modulate disease‑related pathways
- Data output compatible with downstream medicinal chemistry and lead optimization workflows